Lipid mediators in the resolution of inflammation

Cold Spring Harbor Perspectives in Biology

Volumn 7, Issue 2, 2015, Pages

  Serhan, Charles N ^a   Chiang, Nan ^a   Dalli, Jesmond ^a   Levy, Bruce D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; LIPOXIN;

ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; HUMAN; IMMUNOLOGY; INFLAMMATION; LEUKOCYTE; LIPID METABOLISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; HUMANS; INFLAMMATION; LEUKOCYTES; LIPID METABOLISM; LIPOXINS; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL;

EID: 84922575896     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a016311     Document Type: Article

References (151)

1. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. 2005a. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin El. J Exp Med 201: 713-722.
2. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN. 2005b. Resolvin El, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci 102: 7671-7676.
3. Arita M, Oh S, Chonan T, Hong S, Elangovan S, Sun Y-P, Uddin J, Petasis NA, Serhan CN. 2006. Metabolic inactivation of resolvin El and stabilization of its anti-inflammatory actions. J Biol Chem 281: 22847-22854.
4. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. 2007. Resolvin El selectively interacts with leukotriene B4 receptor BUI and ChemR23 to regulate inflammation. J Immunol 178: 3912-3917.
5. Avicenna (Abu Ali Sina adapted by Lalech Bakhtiar). 1999. The canon of medicine [al-Qanun fi'l-tibb]. Great Books of the Islamic World, Chicago.
6. Baillie JK, Digard P. 2013. Influenza—Time to target the host? N Engl J Med 369: 191-193.
7. Bang S, Yoo S, Yang TJ, Cho H, Kim YG, Hwang SW. 2010. Resolvin Dl attenuates activation of sensory transient receptor potential channels leading to multiple anti-no-ciception. Br J Pharmacol 161: 707-720.
8. Bang S, Yoo S, Yang TJ, Cho H, Hwang, SW. 2012. 17(R)-resolvin Dl specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antino-ciception. Br J Pharmacol 165: 683-692.
9. Bannenberg G, Serhan CN. 2010. Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta 1801: 1260-1273.
10. Barnig C, Cernadas M, Dutile S, Liu X, Perrella MA, Kazani S, Wechsler ME, Israel E, Levy BD. 2013. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transi Med 5: 174ral26.
11. Bellenger J, Bellenger S, Bataille A, Massey KA, Nicolaou A, Rialland M, Tessier C, Kang JX, Narce M. 2011. High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: Inflammatory pathway inhibition. Diabetes 60: 1090-1099.
12. Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. 2011. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin Dl and resolvin D2 prevent experimental colitis in mice, J Immunol 187: 1957-1969.
13. Bilal S, Haworth O, Wu L, Weylandt KH, Levy BD, Kang JX. 2011. Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses. Biochim Biophys Acta 1812: 1164-1169.
14. Bohr S, Patel SJ, Sarin D, Irimia D, Yarmush ML, Berthiaume E 2013. Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Repair Regen 21: 35-43.
15. Borgeson E, McGillicuddy FC, Harford KA, Corrigan N, Higgins DF, Maderna P, Roche HM, Godson C. 2012. Lipoxin A4 attenuates adipose inflammation. FASEB J 26: 4287-4294.
16. Brancaleone V, Gobbetti T, Cenac N, le Faouder P, Colom B, Flower RJ, Vergnolle N, Nourshargh S, Perretti M. 2013. Avasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 122: 608-617.
17. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP. 2013. The resolution of inflammation. Nat Rev Immunol 13: 59-66.
18. Calder PC. 2013. Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? Br J Clin Pharmacol 75: 645-662.
19. Chan MM-Y, Moore AR. 2010. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production, J Immunol 184: 6418-6426.
20. Chiang N, Fredman G, Bäckhed F, Oh SF, Vickery TW, Schmidt BA, Serhan CN. 2012. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484: 524-528.
21. Clària J, Dalli J, Yacoubian S, Gao F, Serhan CN. 2012. Resolvin Dl and resolvin D2 govern local inflammatory tone in obese tat. J Immunol 189: 2597-2605.
22. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. 2014. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 307: C39-C54.
23. Cotran, RS, Kumar, V, Collins, T, ed. 1999. Rabbins pathologic basis of disease. W.B. Saunders, Philadelphia.
24. Crawford MA, Broadhurst CL, Guest M, Nagar A, Wang Y, Ghebremeskel K, Schmidt WF. 2013. A quantum theory for the irreplaceable role of docosahexaenoic acid in neural cell signalling throughout evolution. Prostaglandins leukot Essent Fatty Acids 88: 5-13.
25. Dalli J, Serhan CN. 2012. Specific lipid mediator signatures of human phagocytes: Microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120: e60-e72.
26. Dalli J, Winkler JW, Colas RA, Arnardottir H, Cheng CYC, Chiang N, Petasis NA, Serhan CN. 2013a. Resolvin D3 and aspirin-triggered resolvin D3 are potent immuno-resolvents. Chem Biol 20: 188-201.
27. Dalli J, Zhu M, Vlasenko NA, Deng B, Haeggstrom JZ, Petasis NA, Serhan CN. 2013b. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaRl), inhibits leukotriene A4 hydrolase (ITA4H), and shifts macrophage phenotype. FASEB J 27: 2573-2583.
28. Dartt DA, Hodges RR, Li D, Shatos MA, Lashkari K, Serhan CN. 2011. Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins Dl and El to promote resolution of inflammation, J Immunol 186: 4455-4466.
29. De Caterina, R. 2011. n-3 fatty acids in cardiovascular disease. N Engl J Med 364: 2439-2450.
30. Deng B, Wang CW, Arnardottir HH, Li Y, Cheng CY, Dalli J, Serhan CN. 2014. Maresin biosynthesis and identification of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages. PloS ONE 9: el02362.
31. de Paiva CS, Schwartz CE, Gjorstrup P, Pflugfelder SC. 2012. Resolvin El (RX-10001) Reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye. Cornea 31: 1299-1303.
32. Devchand PR, Arita M, Hong S, Bannenberg G, Moussignac R-L, Gronert K, Serhan CN. 2003. Human ALX receptor regulates neutrophil recruitment in transgenic mice: Roles in inflammation and host-defense. FASEB J 17: 652-659.
33. Eickmeier O, Seki H, Haworth O, Hilberath JN, Gao F, Uddin M, Croze RH, Carlo T, Pfeffer MA, Levy BD. 2013. Aspirin-triggered resolvin Dl reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol 6: 256-266.
34. El Kebir D, József L, Pan W, Wang L, Petasis NA, Serhan CN, Filep JG. 2009. 15-Epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med 180: 311-319.
35. El Kebir D, Gjorstrup P, Filep JG. 2012. Resolvin El promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc Natl Acad Sci 109: 14983-14988.
36. Feng Q, Feng F, Feng X, Li S, Wang S, Liu Z, Zhang X, Zhao Q, Wang W. 2012. Resolvin Dl reverses chronic pancreatitis-induced mechanical allodynia, phosphorylation of NMDA receptors, and cytokines expression in the thoracic spinal dorsal horn. BMC Gastroenterol 12: 148.
37. Flower RJ. 2006. Prostaglandins, bioassay and inflammation. Br J Pharmacol 147: S182-S192.
38. Fredman G, Oh SF, Ayilavarapu S, Hasturk H, Serhan CN, Van Dyke TE. 2011. Impaired phagocytosis in localized aggressive periodontitis: Rescue by resolvin El. PLoS ONE 6: e24422.
39. Fredman G, Li Y, Dalli J, Chiang N, Serhan CN. 2012. Self-limited versus delayed resolution of acute inflammation: Temporal regulation of pro-resolving mediators and microRNA. Sci Rep 2: 639.
40. Gao L, Faibish D, Fredman G, Herrera BS, Chiang N, Serhan CN, Van Dyke TE, Gyurko R. 2013. Resolvin El and chemokine-like receptor 1 mediate bone preservation. J Immunol 190: 689-694.
41. Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM, Serhan CN, Mayboroda OA. 2012. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta 1821: 1415-1424.
42. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. 2000. Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages, J Immunol 164: 1663-1667.
43. Gutierrez AD, Sathyanarayana P, Konduru S, Ye Y, Birnbaum Y, Bajaj M. 2012. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis 223: 204-208.
44. Haas-Stapleton, EH, Lu Y, Hong S, Arita M, Favoreto S, Nigam S, Serhan CN, Agabian N. 2007. Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin El. PLoS ONE 2: el316.
45. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. 2008. Resolvin El regulates interleukin-23, interferon-gamma and lipoxin A4 to promote resolution of allergic airway inflammation. Nat Immunol 9: 873-879.
46. Haworth O, Cernadas M, Levy BD. 2011. NK cells are effectors for resolvin El in the timely resolution of allergic airway inflammation. J Immunol 186: 6129-6135.
47. Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M. 2011. Resolvin Dl decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J 25: 2399-2407.
48. Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R, Creager MA, Serhan CN, Conte MS. 2010. Aspirin-triggered lipoxin and resolvin El modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 177: 2116-2123.
49. Hong S, Gronert K, Devchand P, Moussignac R-L, Serhan CN. 2003. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: Autacoids in anti-inflammation. J Biol Chem 278: 14677-14687.
50. Hsiao HM, Sapinoro RE, Thatcher TH, Croasdell A, Levy EP, Fulton RA, Olsen KC, Pollock SJ, Serhan CN, Phipps RP, et al. 2013. A novel anti-inflammatory and pro-resolving role for resolvin Dl in acute cigarette smoke-induced lung inflammation. PLoS ONE 8: e58258.
51. Huang L, Wang C-F, Serhan CN, Strichartz G. 2011. Enduring prevention and transient reduction of post-operative pain by intrathecal resolvin Dl. Pain 152: 557-565.
52. Hudert CA, Weylandt KH, Wang J, Lu Y, Hong S, Dignass A, Serhan CN, Kang JX. 2006. Transgenic mice rich in endogenous n-3 fatty acids are protected from colitis. Proc Natl Acad Sci 103: 11276-11281.
53. Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, Mizuno S, Takagawa T, Morita Y, Kutsumi H, et al. 2010. Resolvin El, an endogenous lipid derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 16: 87-95.
54. Jones CN, Dalli J, Dimisko L, Wong E, Serhan CN, Irimia D. 2012. Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proc Natl Acad Sci 109: 20560-20565.
55. Jones ML, Mark PJ, Keelan JA, Barden A, Mas E, Mori TA, Waddell BJ. 2013. Maternal dietary omega-3 fatty acid intake increases resolvin and protectin levels in the rat placenta. J Lipid Res 54: 2247-2254.
56. Kasuga K, Yang R, Porter TF, Agrawal N, Petasis NA, Irimia D, Toner M, Serhan CN. 2008. Rapid appearance of resolvin precursors in inflammatory exudates: Novel mechanisms in resolution. J Immunol 181: 8677-8687.
57. Keyes KT, Ye Y, Lin Y, Zhang C, Perez-Polo JR, Gjorstrup P, Birnbaum Y. 2010. Resolvin El protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol 299:H153-H164.
58. Kim TH, Kim GD, Jin YH, ParkYS, Park CS. 2012. Omega-3 fatty acid-derived mediator, Resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/ Nga mice. Int Immunopharmacol 14: 384-391.
59. Klein CP, Sperotto ND, Maciel IS, Leite CE, Souza AH, Campos MM. 2014. Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. Neuropharmacology 86C: 57-66.
60. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee C-H, Yang R, Petasis NA, Serhan CN. 2010. Resolvin Dl binds human phagocytes with evidence for pro-resolving receptors. Proc Natl Acad Sci 107: 1660-1665.
61. Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN. 2012. Resolvin Dl receptor stereoselectivity and regulation of inflammation and pro-resolving microRNAs. Am J Pathol 180: 2018-2027.
62. Krishnamurthy VR, Dougherty A, Haller CA, Chaikof EL. 2011. Total synthesis and bioactivity of 18R-hydroxy eicosapentaenoic acid, J Org Chem 76: 5433-5437.
63. Kurihara T, Jones CN, Yu YM, Fischman AJ, Watada S, Tompkins RG, Fagan SP, Irimia D. 2013. Resolvin D2 restores neutrophil directionality and improves survival after burns. FASEB J 27: 2270-2281.
64. Lawrence T, Natoli G. 2011. Transcriptional regulation of macrophage polarization: Enabling diversity with identity. Nat Rev Immunol 11: 750-761.
65. Lawrence T, Willoughby DA, Gilroy DW. 2002. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2: 787-795.
66. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2: 612-619.
67. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt BA, Szczeklik W, Drazen JM, Serhan CN. 2002. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat Med 8: 1018-1023.
68. Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda G, Israel E, Severe Asthma Research Program National Heart Lung and Blood Institute. 2005. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 172: 824-830.
69. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, Kazani S, Israel E, Haley KJ, Serhan CN. 2007. Protectin Dl is generated in asthma and dampens airway inflammation and hyper-responsiveness, J Immunol 178: 496-502.
70. Levy BD, Zhang QY, Bonnans C, Primo V, Reilly JJ, Perkins DL, Liang Y, Arnaout MA, Nikolic B, Serhan CN. 2011. The endogenous pro-resolving mediators lipoxin A4 and resolvin El preserve organ function in allograft rejection. Prostaglandins Leukot Essent Fatty Acids 84: 43-50.
71. Li N, He J, Schwartz CE, Gjorstrup P, Bazan HEP. 2010. Resolvin El improves tear production and decreases inflammation in a dry eye mouse model, J Ocul Pharmacol Ther 26: 431-439.
72. Li D, Hodges RR, Jiao J, Carozza RB, Shatos MA, Chiang N, Serhan CN, Dartt DA. 2013. Resolvin Dl and aspirin-triggered resolvin Dl regulate histamine-stimulated conjunctival goblet cell secretion. Mucosal Immunol 6: 1119-1130.
73. Lima-Garcia J, Dutra R, da Silva K, Motta E, Campos M, Calixto J. 2011. The precursor of resolvin D series and aspirin-triggered resolvin Dl display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br J Pharmacol 164: 278-293.
74. Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M, Chattopadhyay M, La Cava A, Wiedau-Pazos M. 2012. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: Inhibition of inflammation by resolvin Dl. Am J Neurodegener Dis 1: 60-74.
75. Majno G, Joris I. 2004. Cells, tissues, and disease: Principles of general pathology. Oxford University Press, New York.
76. Malawista SE, de Boisfleury Chevance A, van Damme J, Serhan CN. 2008. Tonic inhibition of Chemotaxis in human plasma. Proc Natl Acad Sci 105: 17949-17954.
77. Mas E, Croft KD, Zahra P, Barden A, Mori TA. 2012. Resol-vins Dl, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58: 1476-1484.
78. Mirakaj, V. Dalli, J, Granja, T, Rosenberger, P, Serhan, CN. 2014. Vagus nerve controls resolution and pro-resolving mediators of inflammation. J Exp Med 211: 1037-1048.
79. Miyahara T, Runge S, Chatterjee A, Chen M, Mottola G, Fitzgerald JM, Serhan CN, Conte MS. 2013. D-series re-solvins attenuate vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J 27: 2220-2232.
80. Miyata J, Fukunaga K, Iwamoto R, Isobe Y, Niimi K, Takamiya R, Takihara T, Tomomatsu K, Suzuki Y, Oguma T, et al. 2013. Dysregulated synthesis of protectin Dl in eosinophils from patients with severe asthma, J Allergy Clin Immunol 131: 353-360.
81. Mizwicki, MT, Liu G, Fiala M, Magpantay L, Sayre J, Siani A, Mahanian M, Weitzman R, Hayden E, Rosenthal MJ, et al. 2013. la,25-Dihydroxyvitamin D3 and resolvin Dl retune the balance between amyloid-ß phagocytosis and inflammation in Alzheimer's disease patients, J Alzheimers Dis 34: 155-170.
82. Morita M, Kuba K, Ichikawa A, Nakayama M, Katahira J, Iwamoto R, Watanebe T, Sakabe S, Daidoji T, Nakamura S, et al. 2013. The lipid mediator protectin Dl inhibits influenza virus replication and improves severe influenza. Cell 153: 112-125.
83. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, Newson J, Bellingan G, Gilroy DW. 2009. Effects of low-dose aspirin on acute inflammatory responses in humans, J Immunol 183: 2089-2096.
84. Murakami T, Suzuki K, Tamura H, Nagaoka I. 2011. Suppressive action of resolvin Dl on the production and release of septic mediators in D-galactosamine-sensitized endotoxin shock mice. Exp Ther Med 2: 57-61.
85. Norling LV, Spite M, Yang R, Flower RJ, Perretti M, Serhan CN. 2011. Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing, J Immunol 186: 5543-5547.
86. Norling LV, Dalli J, Flower RJ, Serhan CN, Perretti M. 2012. Resolvin Dl limits polymorphonuclear leukocytes recruitment to inflammatory loci: Receptor dependent actions. Arterioscler Thromb Vasc Biol 32: 1970-1978.
87. Odusanwo O, Chinthamani S, McCall A, Duffey ME, Baker OJ. 2012. Resolvin Dl prevents TNF-a-mediated disruption of salivary epithelial formation. Am J Physiol Cell Physiol 302: C1331-C1345.
88. Ogawa N, Kobayashi Y 2009. Total synthesis of resolvin El. Tetrahedron Lett 50: 6079-6082.
89. Ogawa N, Kobayashi Y. 2011. Total synthesis of the antiinflammatory and proresolving protectin Dl. Tetrahedron Lett 52: 3001-3004.
90. Ogawa S, Urabe D, Yokokura Y, Arai H, Arita M, Inoue M. 2009. Total synthesis and bioactivity of resolvin E2. Org Lett 11: 3602-3605.
91. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. 2011. Proresolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest 121: 569-581.
92. Oh SF, Dona M, Fredman G, Krishnamoorthy S, Irimia D, Serhan CN. 2012. Resolvin E2 formation and impact in inflammation resolution, J Immunol 188: 4527-4534.
93. Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. 2010. Resolvin El receptor activation signals phosphorylation and phagocytosis, J Biol Chem 285: 3451-3461.
94. Palmer CD, Mancuso CJ, Weiss JP, Serhan CN, Guinan EC, Levy, O. 2011. 17(R)-Resolvin Dl differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J Leukoc Biol 90: 459-470.
95. Park CK, Lü N, Xu ZZ, Liu T, Serhan CN, Ji RR. 2011. Resolving TRPV1 and TNF-a-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotec-tin Dl. JNeurosci 31: 15072-15085.
96. Peebles RS Jr. 2013. A new horizon in asthma: Inhibiting ILC function. Sci Transi Med 5: 174fs7.
97. Perretti M, D'Acquisto F. 2009. Annexin AI and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9: 62-70.
98. Pillai PS, Leeson S, Porter TF, Owens CD, Kim JM, Conte MS, Serhan CN, Gelman S. 2012. Chemical mediators of inflammation and resolution in post-operative abdominal aortic aneurysm patients. Inflammation 35: 98-113.
99. Prescott D, McKay DM. 2011. Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am J Physiol Gastrointest Liver Physiol 301: G487-G497.
100. Pruss H, Rosche B, Sullivan AB, Brommer B, Wengert O, Gronert K, Schwab JM. 2013. Proresolution lipid mediators in multiple sclerosis—Differential, disease severity-dependent synthesis—A clinical pilot trial. PLoS ONE 8: e55859.
101. Psychogios N, Hau DD, Peng J, Guo AC, Mandai R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, et al. 2011. The human serum metabolome. PLoS ONE 6: el6957.
102. Qu X, Zhang X, Yao J, Song J, Nikolic-Paterson DJ, Li J. 2012. Resolvins El and Dl inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation. J Pathol 228: 506-519.
103. Quan-Xin F, Fan F, Xiang-Ying F, Shu-Jun L, Shi-Qi W, Zhao-Xu L, Xu-Jie Z, Qing-Chuan Z, Wei W. 2012. Re-solvin Dl reverses chronic pancreatitis-induced mechanical allodynia, phosphorylation of NMDA receptors, and cytokines expression in the thoracic spinal dorsal horn. BMC Gastroenterol 12: 148.
104. Rajasagi NK, Reddy PBJ, Suryawanshi A, Mulik S, Gjorstrup P, Rouse BT. 2011. Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. J Immunol 186: 1735-1746.
105. Recchiuti A, Serhan CN. 2012. Pro-resolving lipid mediators (SPMs) and their actions in regulating miRNA in novel resolution circuits in inflammation. Front Immun 3: 298.
106. Recchiuti A, Krishnamoorthy S, Fredman G, Chiang N, Serhan CN. 2011. MicroRNAs in resolution of acute inflammation: Identification of novel resolvin Dl-miRNA circuits. FASEB J 25: 544-560.
107. Rodriguez AR, Spur BW. 2012a. First total synthesis of the anti-inflammatory lipid mediator Resolvin D6. Tetrahedron Lett 53: 86-89.
108. Rodriguez AR, Spur BW. 2012b. Total synthesis of the antiinflammatory lipid mediator Resolvin E2. Tetrahedron Lett 53: 1912-1915.
109. Rodriguez AR, Spur BW. 2012c. Total synthesis of the macrophage derived anti-inflammatory lipid mediator Maresin 1. Tetrahedron Lett 53: 4169-4172.
110. Rogerio AP, Haworth O, Croze R, Oh SF, Uddin M, Carlo T, Pfeffer MA, Priluck R, Serhan CN, Levy BD. 2012. Resolvin Dl and aspirin-triggered resolvin Dl promote resolution of allergic airways responses, J Immunol 189: 1983-1991.
111. Samuelsson B. 2012. Role of basic science in the development of new medicines: Examples from the eicosanoid field, J Biol Chem 287: 10070-10080.
112. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. 1987. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 237: 1171-1176.
113. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, Mastalerz L, Serhan, CN, Szczeklik, A. 2000. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 16: 44-49.
114. Schwab JM, Chiang N, Arita M, Serhan CN. 2007. Resolvin El and protectin Dl activate inflammation-resolution programmes. Nature 447: 869-874.
115. Seki H, Fukunaga K, Arita M, Arai H, Nakanishi H, Taguchi R, Miyasho T, Takamiya R, Asano K, Ishizaka A, et al. 2010. The anti-inflammatory and proresolving mediator resolvin El protects mice from bacterial pneumonia and acute lung injury. J Immunol 184: 836-843.
116. Serhan CN. 2004. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: Missing links to resolution. Histochem Cell Biol 122: 305-321.
117. Serhan CN, guest ed. 2005. Special issue on lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot Essent Fatty Acids 73: 139-321.
118. Serhan CN. 2007. Resolution phases of inflammation: Novel endogenous anti-inflammatory and pro-resolving lipid mediators and pathways. Annu Rev Immunol 25: 101-137.
119. Serhan CN. 2011. The resolution of inflammation: The devil in the flask and in the details. FASEB J 25: 1441-1448.
120. Serhan CN. 2014. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510: 92-101.
121. Serhan CN, Chiang N. 2013. Resolution phase lipid mediators of inflammation: Agonists of resolution. Curr Opin Pharmacol 13: 632-640.
122. Serhan CN, Petasis NA. 2011. Resolvins and protectins in inflammation-resolution. Chem Rev 111: 5922-5943.
123. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192: 1197-1204.
124. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac R-L. 2002. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 196: 1025-1037.
125. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. 2009. Maresins: Novel macrophage mediators with potent anti-inflammatory and pro-resolving actions. J Exp Med 206: 15-23.
126. Serhan CN, Ward PA, Gilroy DW, ed. 2010. Fundamentals of inflammation. Cambridge University Press, New York.
127. Serhan CN, Fredman G, Yang R, Karamnov S, Belayev LS, Bazan NG, Zhu M, Winkler JW, Petasis NA. 2011. Novel proresolving aspirin-triggered DHA pathway. Chem Biol 18: 976-987.
128. Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ, Ji RR, Zhu M, Petasis NA. 2012. Macrophage pro-resolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J 26: 1755-1765.
129. Settimio R, Clara DF, Franca F, Francesca S, Michele D. 2012. Resolvin D1 reduces the immunoinflammatory response of the rat eye following uveitis. Mediators Inflamm 2012: 318621.
130. Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN. 2009. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461: 1287-1291.
131. Sun Y-P, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, Colgan SP, Petasis NA, Serhan CN. 2007. Resolvin D1 and its aspirin-triggered 17R epimer: Stereochemical assignments, anti-inflammatory properties and enzymatic in-activation. J Biol Chem 282: 9323-9334.
132. Tabas I, Glass CK. 2013. Anti-inflammatory therapy in chronic disease: Challenges and opportunities. Science 339: 166-172.
133. Takano T, Clish CB, Gronert K, Petasis N, Serhan CN. 1998. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest 101: 819-826.
134. Tang Y, Zhang MJ, Hellmann J, Kosuri M, Bhatnagar A, Spite M. 2013. Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 62: 618-627.
135. Tauber AI, Chernyak L. 1991. Metchnikoff and the origins of immunology: From metaphor to theory. Oxford University Press, New York.
136. Terrando N, Gomez-Galan M, Yang T, Carlstrom M, Gustavsson D, Harding RE, Lindskog M, Eriksson LI. 2013. Aspirin-triggered resolvin Dl prevents surgery-induced cognitive decline. FASEB J 27: 3564-3571.
137. Titos E, Rius B, Gonzalez-Périz A, Lopez-Vicario C, Moran-Salvador E, Martinez-Clemente M, Arroyo V, Claria J. 2011. Resolvin Dl and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by elicitying macrophage polarization toward a pro-resolving phenotype. J Immunol 187: 5408-5418.
138. Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray IP, Ko DC, Zou Y, Bang ND, Chau TT, et al. 2012. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148:434-446.
139. Vong L, Ferraz JG, Dufton N, Panaccione R, Beck PL, Sherman PM, Perretti M, Wallace JL. 2012. Up-regulation of Annexin-Al and lipoxin A4 in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS ONE 7: e39244.
140. von Moltke J, Trinidad NJ, Moayeri M, Kintzer AF, Wang SB, van Rooijen N, Brown CR, Krantz BA, Leppla SH, Gronert K, et al. 2012. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 490: 107-111.
141. Walker J, Dichter E, Lacorte G, Kerner D, Spur B, Rodriguez A, Yin K. 2011. Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. Shock 36: 410-416.
142. Wang SB, Hu KM, Seamon KJ, Mani V, Chen Y, Gronert K. 2012. Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea. FASEB J 26: 1506-1516.
143. Wang X, Zhu M, Hjorth E, Cortés-Toro V, Eyjolfsdottir H, Graff C, Nennesmo I, Palmblad J, Eriksdotter M, Sambamurti K, et al. 2014. Resolution of inflammation is altered in Alzheimer's disease. Alzheimer's Dement doi: 10.1016/j.jalz.2013.1012.1024.
144. Weiss GA, Troxler H, Klinke G, Rogier D, Braegger C, Hersberger M. 2013. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis 12: 89.
145. Wu S-H, Liao P-Y, Yin P-L, Zhang Y-M, Dong L. 2009. Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. Am J Pathol 174: 115-122.
146. Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. 2013. Efficacy and safety of 15(R/S)-methyl-lipoxin A4 in topical treatment of infantile eczema. Br J Dermatol 168: 172-178.
147. Xu Z-Z, Zhang L, Liu T, Park J-Y, Berta T, Yang R, Serhan CN, Ji R-R. 2010. Resolvins RvEl and RvDl attenuate inflammatory pain via central and peripheral actions. Nat Med 16: 592-597.
148. Xu ZZ, Berta T, Ji RR. 2013. Resolvin El inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury, J Neuroimmune Pharmacol 8: 37-41.
149. Yamaguchi H, Higashi N, Mita H, Ono E, Komase Y, Nakagawa T, Miyazawa T, Akiyama K, Taniguchi M. 2011. Urinary concentrations of 15-epimer of lipoxin A4 are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. Clin Exp Allergy 41:1711-1718.
150. Yanes O, Clark J, Wong DM, Patti GG, Sanchez-Ruiz A, Benton HP, Trauger SA, Desponts C, Ding S, Siuzdak G. 2010. Metabolic oxidation regulates embryonic stem cell differentiation. Nat Chem Biol 6: 411-417.
151. Zivkovic AM, Yang J, Georgi K, Hegedus C, Nording ML, O'Sullivan A, German JB, Hogg RJ, Weiss RH, Bay C, et al. 2012. Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations. Metabolomics 8: 1102-1113.